Healthy Participants
Conditions
Brief summary
Study to determine the effect of multiple-dose BBT-877 on the single-dose pharmacokinetics of midazolam, the safety and tolerability of a single dose of BBT-877 administered alone and with multiple doses of itraconazole, and the effect of multiple-dose esomeprazole on the single-dose pharmacokinetics of BBT-877, in healthy adult subjects.
Interventions
DRUGBBT-877
BBT-877 oral capsule.
DRUGMidazolam
Midazolam oral syrup.
DRUGItraconazole
Itraconazole oral capsule.
DRUGEsomeprazole
Esomeprazole oral capsule.
Sponsors
KCRN Research, LLC
Bridge Biotherapeutics, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy adult male and/or female (non-childbearing potential only), 19 to 55 years of age, inclusive, at screening. 2. Continuous non-smoker who has not used nicotine-containing products for at least 3 months prior to the first dose and throughout the study. 3. BMI ≥ 18.5 and ≤ 32.0 kg/m2 and weight ≥ 50 kg at screening. 4. Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs, as deemed by the PI or designee. 5. No clinically significant history or presence of ECG findings as judged by the PI or qualified designee at screening and first check-in. 6. For a female, must be of non-childbearing potential. 7. A non-vasectomized, male subject must agree to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days beyond the last dose of study drug. 8. If male, must agree to not donate sperm from the first dose until 90 days after the last dose of study drug(s). 9. Must have the ability to understand and sign a written informed consent form (ICF), which must be obtained prior to initiation of study procedures, and be willing and able to comply with the protocol requirements as outlined in the ICF.
Exclusion criteria
1. Subject is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study. 2. History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee. 3. History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study. 4. History or presence of alcoholism or drug abuse within the past 2 years prior to the first dose or regular alcohol consumption within 6 months prior to the first dose. 5. History or presence of hypersensitivity or idiosyncratic reaction to the study drug(s) or related compounds. 6. History of anemia or history of decreased red blood cells (RBC). 7. Estimated creatinine clearance \<80 mL/min at screening. 8. Liver function tests (serum ALT, AST, alkaline phosphatase) and serum bilirubin (total and direct) \> upper limit of normal at screening or first check-in. 9. Baseline hemoglobin, hematocrit, RBC \< lower limit of normal at screening and Day -1 of Period 1. 10. Female subjects who are of childbearing potential. 11. Female subjects who are pregnant or lactating. 12. Positive urine drug or alcohol results at screening or first check-in. 13. Positive urine cotinine at screening. 14. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (HCV).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AUC (the area under the curve) [Pharmacokinetics] | Day 1 of period 1 and Day 10 (Arm 1), 5 (Arm 2), or 5 (Arm 3) of period 2 | AUC for midazolam and 1-OH-midazolam with and without BBT-877 (Arm 1), and for BBT-877 with and without itraconazole (Arm 2) or esomeprazole (Arm 3) |
| Cmax (peak concentration) [Pharmacokinetics] | Day 1 of period 1 and Day 10 (Arm 1), 5 (Arm 2), or 5 (Arm 3) of period 2 | Cmax for midazolam and 1-OH-midazolam with and without BBT-877 (Arm 1), and for BBT-877 with and without itraconazole (Arm 2) or esomeprazole (Arm 3) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Plasma LPA (Lysophosphatidic acid) concentration [Pharmacodynamics (Arm 2 and 3)] | Day 1 of period 1 and Day 10 (Arm 1), 5 (Arm 2), or 5 (Arm 3) of period 2 | plasma LPA (18:2 and 20:4) concentrations over time and percent decrease from baseline LPA level |
| Incidence of adverse events [Safety and tolerability] | Up to 14 days after the last study drug administration | Incidence of adverse events |
Countries
United States
Outcome results
None listed